<DOC>
	<DOC>NCT01160120</DOC>
	<brief_summary>The purpose of this study is to determine the mid levels of the tenofovir, lamivudine, and efavirenz, and 144 weeks safety and efficacy of the generic fixed dose combination of tenofovir /lamivudine/efavirenz tablets 300/300/600 mg in Thai HIV-infected patients.</brief_summary>
	<brief_title>Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz</brief_title>
	<detailed_description>The trial drug FDC of TDF/3TC/EFV is a new formulation combining fixed doses of the nucleoside reverse transcriptase inhibitors lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg with the non nucleoside reverse transcriptase inhibitor efavirenz 600 mg for once daily and one-tablet HAART. Co-formulated TDF/3TC/EFV demonstrated bioequivalent to original individual EFV 3TC and TDF in Indian healthy volunteers (unpublished data). It has not been evaluated in clinical trials.</detailed_description>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Signed informed consent Evidence of HIV infection Age&gt; 18 years On a TDF/3TC/EFV (separated pills) containing HAART regimen with a VL &lt; 50 copies within 24 weeks or ARV na√Øve eGFR &gt;70 cc/min Currently having no AIDS defining illness No history of NRTI/NNRTI/PI failure Willing to adhere to the protocol requirements Any history of taking CYP450 inhibitors or inducers drugs within 14 days of enrollment in the study Current pregnancy or lactating or plan to be pregnant Active opportunistic infection ALT more than 2 x upper limit Creatinine more than 1.5 time the upper limit Active drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>fixed dose combinations</keyword>
	<keyword>tenofovir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>efavirenz</keyword>
	<keyword>therapeutic drug levels</keyword>
	<keyword>safety and efficacy</keyword>
	<keyword>HIV</keyword>
	<keyword>To evaluation new formulations of FDC of TDF/3TC/EFV</keyword>
</DOC>